NEW YORK — SpeeDx said on Thursday that it has signed a distribution agreement for its ResistancePlus and PlexPCR diagnostic tests in Turkey.
Under the terms of the deal, Neogen Diagnostik will distribute the tests throughout Turkey. Additional terms were not disclosed.
The ResistancePlus tests are designed to detect both infection and genetic markers of antibiotic resistance. The product line includes the CE-marked tests ResistancePlus GC for Neisseria gonorrhoeae and ciprofloxacin susceptibility, and ResistancePlus MG for Mycoplasma genitalium and azithromycin resistance.
The PlexPCR portfolio includes PlexPCR VHS, a multiplex test for herpes simplex virus (HPV) 1 and 2, varicella zoster (VZV), and Treponema pallidum, as well as a multiplex panel called PlexPCR HSV-1 & 2, VZV that detects and differentiates HSV and VZV. Both of these tests are also CE marked.
SpeeDx also recently launched PlexPCR RespiVirus, a multiplex respiratory panel that detects and differentiates influenza A and B, respiratory syncytial virus A and B, rhinovirus, parainfluenzas 1 through 4, adenovirus, and human metapneumovirus. The Sydney, Australia-based company said it is also planning to introduce a dual-target COVID-19 assay called PlexPCR SARS-CoV-2.
In early 2019, SpeeDx signed a distribution pact for the ResistancePlus and PlexPCR products in the Middle East with Al Zahrawi Medical Supplies.